A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
Status:
Completed
Trial end date:
2018-06-15
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the pharmacokinetics, safety, tolerability and
immunogenicity following a single intravenous (IV) infusion of risankizumab in healthy
Japanese and Caucasian participants.